04:58 PM EDT, 04/15/2024 (MT Newswires) -- Edgewise Therapeutics ( EWTX ) said late Monday that an open-label trial of sevasemten in adults with Becker muscular dystrophy showed "positive" two-year topline results.

Sevasemten was well-tolerated in 12 participants with no adverse event-related discontinuation or dose reductions, the firm said.

The results from the trial further support the hypothesis that a reduction in contraction-induced muscle damage in muscular dystrophies has the potential to preserve function and halt disease progression in Becker, Edgewise said.